Glide Technologies and Cilian AG partner for innovative influenza vaccine
Glide Technologies is a development company that previously concentrated on solid dose formulations of both vaccines as well as therapeutics. The partnership with Cilian AG, a German biotechnology company, will allow CiFlu to be used with SDI, Glide’s patient-friendly delivery device.
The beginning results from this partnership show that CiFlu has a strong room-temperature stability. Preclinical potency testing will be used to confirm that the vaccine has promise in provoking a strong immune response.
Cilian used a unicellular organism, Tetrahymena thermophile, to create the recombinant DNA technology. This is meant to improve the reliability, speed and quality of production.
As of today, influenza vaccines are made every year according to various changes that the circulating virus undergoes over time. The traditional production rate can last for 28 weeks, which can cause delays when it comes to administering the vaccine to vulnerable groups of people.
A new way to produce vaccines, like CiFlu, could decrease the rate of production by approximately 10 weeks. This would serve to benefit the vaccine industry as well as influenza patients around the world.